Health Care • Biotechnology: Pharmaceutical Preparations
$12.15 ▲ +0.08
(+0.66%)
MKT CAP: $345.3M • VOL: 474.8K
52W L $6 52W H $18
ARCT // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $82.0M | $152.3M | $166.8M |
| YoY Revenue Growth % | -46.1% | -8.7% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$76.3M | -$95.7M | -$78.2M |
| Operating Margin % | -80.0% | -62.8% | -46.9% |
| Net Income (GAAP) | -$65.8M | -$80.9M | -$29.7M |
| EBITDA (Normalized) | -$76.1M | -$95.2M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$74.3M | -$59.7M | -$18.1M |
| Capital Expenditures (CapEx) | $230.0K | $648.0K | — |
| Free Cash Flow (FCF) | -$74.5M | -$60.4M | -$18.1M |
| FCF Margin % | -80.0% | -39.7% | -10.9% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $230.9M | $237.0M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $214.0M | $241.0M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR ARCT.